Abstract
Background
The Lung Cancer Disease Site Group (Lung DSG) of the Cancer Care Ontario (CCO) Program in Evidence-based Care (PEBC) has developed a clinical practice guideline, based on a systematic review of the evidence, for the medical use of postoperative chemotherapy in completely resected NSCLC (Alam et al., 2006) . That guideline recommended cisplatin-based chemotherapy as postoperative treatment for patients with completely resected stage II or IIIA disease who are considered fit enough for chemotherapy. Therapy was not recommended for patients with stage IB disease.
These treatment recommendations have broader implications for the management of patients, because chemotherapy-related toxicities need to be appropriately assessed and managed for patients to receive the optimal benefits of therapy. The practice guideline report emphasizes that the potential benefits, limitations, and toxicity of adjuvant treatment should be fully discussed with patients, and the importance of effective management of disease and treatment-related symptoms is increasingly recognized (Alam et al., 2006) . Members of the Lung DSG noted that there is a widely recognized difficulty keeping patients on adjuvant therapy, because of side effects. Nurses fill a number of roles across the continuum of care, including counselling patients on issues related to treatment completion, providing education directed towards the prevention of side effects, assessing and managing symptoms of the disease or previous surgery, and follow-up. Believing that a nursingspecific perspective related to these concerns was necessary to improve care for NSCLC patients receiving adjuvant chemotherapy, the Lung DSG members initiated this nursing guidance report.
This report is intended to be a resource for nurses caring for patients with NSCLC who are receiving adjuvant chemotherapy. In this report, we review the evidence on toxicity and adverse events from adjuvant chemotherapy and highlight priority side effects that are amenable to nursing assessment and intervention. For each of the major side effects, assessment and management strategies are highlighted, as is advice for meeting patients' informational, physical, and emotional needs throughout the treatment trajectory. The Standards of Care developed by the Canadian Association of Nurses in Oncology/L'Association canadienne des infirmières en Oncologie (CANO/ACIO) detail key aspects of effective practice in this setting and form a basis for the advice provided in this report (Canadian Association of Nurses in Oncology, 2002) .
Methods
A systematic review and clinical practice guideline on adjuvant chemotherapy in resected NSCLC was developed by the Lung DSG in 2006 (Alam et al., 2006) . This nursing document was initiated as an adjunct to that report. A literature search strategy was designed to identify published nursing practice guidelines and evidence-based reports that addressed care for patients with NSCLC receiving chemotherapy. While a structured literature search was conducted for published practice guidelines on topics in lung cancer nursing, the two guidelines found were not based on evidence or specific to the scope of this report (The London and South East Lung Cancer Forum for Nurses, 2004; Quinn, 1999) . Instead, therefore, the Lung DSG developed nursing-specific guidance on this topic by utilizing evidence retrieved in the medical practice guideline report (Alam et al., 2006) , general principles established by CANO/ACIO for nursing oncology practice (Canadian Association of Nurses in Oncology, 2002) , the Fitch model identifying patient and family domains of need across the cancer care continuum (Fitch, 2003; Fitch, 1994) , and the clinical experiences of Lung DSG members.
Guidance
Standards of care, nursing roles, and competencies CANO/ACIO statements on nursing standards, roles, and competencies underpin quality nursing practice for patients with lung cancer. These statements are broad in their scope and are applicable to nurses working across all disease sites, including lung cancer. Although the CANO/ACIO statements are valuable as broad guiding principles for nursing practice, more specific guidance is needed on issues that arise in the care of patients receiving adjuvant chemotherapy for resected NSCLC. Lung DSG members reviewed and extended the CANO/ACIO standards of care in order to develop practice-specific guidance for nurses working in this setting. The CANO/ACIO standards reflect the belief that patients are entitled to the following care elements: individualized and holistic care; familycentred care; self-determination and access to information to enable decision-making; seamless, coordinated, and continuous care involving open lines of communication and access to the interdisciplinary team; supportive, knowledgeable, and professional therapeutic relationships; and evidence-based and ethical care in which meticulous symptom management and health promotion is the primary focus. The Lung DSG recommends that nurses caring for patients receiving adjuvant chemotherapy for resected NSCLC adhere to these statements in their practice.
In addition, the Fitch model (Fitch, 1994) , which integrates six identified patient and family domains of need (physical, emotional, informational, psychosocial, spiritual, and practical) with nine points of care delivery across the continuum of the cancer journey (prediagnosis, diagnosis, dialogue/referral, treatment, rehabilitation, survivorship, recurrent disease, palliation, and bereavement) is a useful conceptual tool to guide nursing practice and underpins much of the following guidance (Fitch, 2003; Fitch, 1994) . As the model indicates, individuals enter the cancer care delivery system at various points and experience the journey in different ways over time. As patients and their family members move along the cancer care trajectory, they bring their physical, emotional, psychological, social, informational, practical, and spiritual needs with them. These needs ebb and flow as a result of the disease itself, treatment effects and toxicities, and interactions with health care personnel. At each phase of the cancer journey, needs will emerge, change in intensity and resolve. If needs remain unmet, patients continue to experience physical and or emotional distress and upheaval. Emotional and physical distress can magnify and compromise compliance with cancer therapy (Carlson & Bultz, 2004; Douillard et al., 2005; Shepherd et al., 2004) and increase patients' use of community health services and visits to emergency departments (Carlson & Bultz, 2004; Kurtz, Kurtz, Given, & Given, 2006) .
Beginning adjuvant treatment
Application of Fitch's Supportive Care Model (Fitch, 2003; Fitch, 2004) and guidance through the CANO/ACIO documents help the oncology nurse to meet the following identified patient needs. The need for information is high as patients and their families enter the cancer care trajectory at the treatment phase. The need for emotional and spiritual support may remain constant throughout the course of the illness, and Rates of psychological distress are highest among patients with lung cancer when compared to other types of cancer (Zabora, Brintzenhofeszoc, Curbow, & Piantadosi, 2001 ). Depression and anxiety can begin at diagnosis, during the peri-operative period or in the first year post-surgery (Newell, Sanson-Fisher, & Savolainen, 2002; Yosuke et al., 2003) . Because there may be guilt from smoking, morbidity from surgery or a potentially poor prognosis, it is essential that nurses assess patients for their psychosocial, spiritual, and practical needs and develop appropriate management strategies based on institutional and national evidence-based guidelines. As well, nurses should facilitate access to specialized professionals (e.g., social workers, spiritual care providers, supportive services and networks, peer support). Ongoing evaluation of the effectiveness of implemented management strategies is vital to ensure psychosocial, spiritual, and practical needs are met. Having these needs addressed enables patients to better manage their own needs and allows them to cope with the demands imposed by their illness and treatments (Newell et al., 2002) . Continuity of nursing care is recommended during adjuvant treatment, as patients are often seen by many different health professionals, which can be a source of stress and patient dissatisfaction (National Cancer Alliance, 1996) .
Post-surgical rehabilitation can be introduced before the initiation of adjuvant treatment. Breathlessness post surgery can be effectively assessed and managed by nurses with non-pharmacologic interventions and should be implemented (Bredin et al., 1999) . Smoking cessation should also be discussed with patients and their families throughout the cancer journey. This is a source of added anxiety, stress and guilt for patients. As most surgeons emphasize smoking cessation preoperatively, the role of the nurse should be to reinforce smoking cessation after surgery and ensure the patient has access to appropriate information, referrals, and psychosocial support. Nurses can look to The Registered Nurses Association of Ontario (RNAO) best practice guideline on "Integrating smoking cessation into daily nursing practice" (RNAO, 2007) to develop this competency.
Treatment-related toxicities common to patients receiving adjuvant chemotherapy
Chemotherapy toxicities impact upon patients' quality of life, morbidities, and ability to complete planned treatment. The completion of chemotherapy has been a major issue in clinical trials of adjuvant therapy, with major trials reporting only 50% to 70% of patients receiving the planned chemotherapy dose (Douillard et al., 2006; Winton et al., 2005) . A multivariate analysis found statistically significant differences in completion on the basis of extent of surgery, gender and age. Women, the elderly, and patients with pneumonectomy were less likely to complete therapy (Alam et al., 2005) . Of particular concern are the grade three or four toxicities reported in more than 5% of patients receiving adjuvant cisplatinvinorelbine (Table One) . These include febrile neutropenia, thrombocytopenia, and anemia (Douillard et al., 2006; Winton et al., 2005) . Malaise or fatigue is the most common (81%) and the most severe (15%) non-hematologic toxicity associated with cisplatinvinorelbine . The oncology nurse should keep these factors in mind when supporting patients through treatment.
Nursing assessment of treatment-related toxicities
During the course of treatment, the oncology nurse plays a critical role in the prevention and early detection of treatment toxicities that impact upon patient quality of life, functional and emotional status, self-care ability, co-morbidities, and ability to complete planned treatment. A focused history and physical assessment prior to the initiation of chemotherapy, and then during the course of treatment, is necessary to determine treatment toxicities and their impact upon patients over time. In addition to treatment-related toxicities, the oncology nurse must also be aware of other common symptoms, which patients may have from the disease itself or as a result of having had a thoracotomy, such as incisional or neuropathic pain. It is also known that 15% to 44% of all patients diagnosed with lung cancer have some form of depression (Cooley, 2000; Ginsburg, Quirt, Ginsburg, & MacKillop, 1995; Yosuke et al., 2003) . In addition, sleep-wake disturbances are also common in newly diagnosed lung cancer patients (Cooley, 2000) .
Because of the large number of assessment tools available, each Lung Disease Site Team should identify those tools they feel are most useful in their practice and use them consistently to ensure familiarity and usefulness. CCO has mandated that the Edmonton Symptom Assessment Scale (ESAS) be used on all cancer patients. This scale provides an overview of common symptoms in patients with cancer and is easy to complete. Since fatigue is common and may lead to noncompliance with completion of multiple assessment tools, the ESAS provides an opportunity to explore or measure further only those most problematic symptoms and still elicit objective information through a comprehensive assessment. Table Two outlines some other short-item scales and easy-to-complete measurement tools that provide objective information about the emergence and severity of side effects, and the effectiveness of symptom and distress management.
Nursing intervention for treatment-related toxicities
Optimal nursing management of treatment toxicities should be initiated before the provision of chemotherapy. Patient education related to the prevention and alleviation of treatment toxicity associated with adjuvant cisplatin-vinorelbine may enable patient participation in self-monitoring for the purpose of early detection and prompt reporting of symptoms and concerns. Nurses should be aware of factors that modify treatment compliance (e.g., co-morbidities, extent of surgery, gender and age) and should assist patients in completing treatment through the early detection and meticulous management of treatment toxicities.
Nursing interventions related to the assessment, prevention, and alleviation of chemotherapy toxicities associated with cisplatinvinorelbine have been thoroughly addressed, and management strategies can be found in the Telephone Nursing Practice and Symptom Management Guidelines posted on the CCO website (http://www.cancercare.on.ca/documents/NursingTelephonePractice Guidelines.pdf), the National Comprehensive Cancer Network website (http://www.nccn.org/default.asp), and the Oncology Nursing Society (ONS) website (http:www.ons.org/outcomes/measures/ summaries.shtml).
Follow-up care
Nurses play a key role in the follow-up and rehabilitation of patients following adjuvant treatment for lung cancer. Rehabilitation may occur within medical or surgical oncology practice or in a doi:10.5737/1181912x18315 primary care setting. In addition to providing medical surveillance, nurses are well equipped to provide follow-up on many of the toxicity-related consequences affecting patients who have received adjuvant chemotherapy. A randomized trial of follow-up in lung cancer patients found improved patient satisfaction, earlier detection of symptom progression, better scores for emotional functioning, less severe dyspnea, less peripheral neuropathy, and fewer physician consults in patients also followed by a nurse, compared with patients impairment, that comprises a 5-point activity evaluation, with an overall score of 0-5 (Oken et al., 1982) (0=normal, 5=dead)
Symptoms
Edmonton Symptom http://www.palliative.org/pc/clinicalinfo/assessmenttools/esas.pdf -Items are patient responses to Assessment Scale (ESAS) severity of 9 symptoms, as reported on a 10 cm VAS (visual analog scale). ESAS correlates closely with physical symptom subscales in the Functional Assessment of Cancer Therapy (FACT), the Memorial Symptom Assessment Scale (MSAS), and with the KPS.
Lung Cancer Symptom Scale http://www.lcss-ql.com/ -LCSS score comprises the aggregate scores of 9 patient items (LCSS) (10 cm VAS), and six observer items (5-point rating scale). The scale emphasizes physical and functional QOL dimensions, has good sensitivity to all levels of the KPS, and is site specific.
Symptom Distress
The Memorial Symptom http://www.promotingexcellence.org/i4a/pages/Index.cfm?pageID=3410 Patients rate the frequency, Assessment Scale (MSAS) severity, and distress associated with 32 prevalent symptoms in cancer patients, experienced during the previous week. The scoring provides several validated subscale scores for overall symptom distress, physical symptoms, and psychological symptoms.
Pain Intensity
The Brief Pain Inventory (BPI) http://www.mdanderson.org/departments/prg/display.cfm?id=0EE7830A-6646-11D5-812400508B603A14&pn=0EE78204-6646-11D5-812400508B603A14&method=displayfull -Patient rates pain intensity with a numeric 0-10 scale (0=no pain, 10= worst possible pain) and the impact pain exerts on daily activity, mood, walking, sleeping, movement, enjoyment of life and relationships with others.
Depression
Hospital Anxiety And http://www.hqlo.com/content/1/1/29 -Instrument designed to detect the presence and severity of Depression Scale (HADS) mild degrees of mood disorder, anxiety and depression. Scores of 0-7 in respective subscales are considered normal, with 8-10 borderline and 11 or over indicating clinical 'caseness'.
Dyspnea
Modified Borg Scale http://ajrccm.atsjournals.org/cgi/content/full/158/5/1557 -This 0 to 10 rated scale has the potential to provide quick, easy, and rapid information about a patient's subjective state of dyspnea. who received only conventional medical follow-up (Moore et al., 2002) . Nurses must address a number of issues in conducting followup, including providing information on the importance of follow-up care and its specific goals; pain management; smoking cessation; general cancer-treatment-related disorders including fatigue, physical disability due to surgery or deconditioning, sexual dysfunction, neurologic and musculoskeletal disorders, hearing loss, and cognitive impairment; healthy lifestyle education; issues related to decreased lung capacity; supportive counselling; and signs and symptoms that may indicate cancer recurrence.
Nurses should provide information and support to patients as they deal with returning to work, and other survivorship issues. Lung Cancer Online provides information on common survivorship issues and how to support patients at this point in the continuum of care (http://www.lungcanceronline.org/surviving/index.html). Nurse-led follow-up clinics for patients who have completed adjuvant chemotherapy should be considered. Further research is required to determine the frequency and nature of the health monitoring required to properly support patients with consistent follow-up care.
Conclusion
Members of the Lung DSG noted that in their clinical practice, it was difficult for patients to complete adjuvant cisplatin/vinorelbine chemotherapy due to the side effects and felt that nursing-specific guidance related to these concerns would aid in improving care for these patients. This report highlights the evidence on the toxicity and adverse events that are caused by adjuvant chemotherapy and discusses major side effects and symptoms that are amenable to nursing assessment and intervention. Oncology nurses are vital, whether in the primary or navigator roles, to communicate the importance of treatment completion to patients, to help remedy toxicity, and to support patients and families across the continuum of care.
